Please assess the completion status of the following clinical trial:

Trial Title: A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Has a diagnosis by the study investigator of a clinical syndrome of cognitive impairment consistent with prodromal AD per International Working Group (IWG) diagnostic criteria or mild cognitive impairment (MCI) due to AD per National Institute on Aging-Alzheimer's Association (NIA-AA) diagnostic criteria.~* Scores 17-28 on Montreal Cognitive Assessment (MoCA) at screening.~* Scores \<27 on free recall cutoff score from the Free and Cued Selective Reminding Test (FCSRT) (Picture version) at screening.~* Scores ≤4 on Modified Hachinski Ischemia Scale (MHIS).~* Scores \>0 on the Functional Activities Questionnaire (FAQ).~* Has a florbetapir positron emission tomography (PET) scan or cerebrospinal fluid (CSF) result at screening consistent with the presence of amyloid pathology.~Exclusion Criteria:~* Has had MRI or computerized tomography (CT) of brain within previous 2 years showing pathology that would be inconsistent with a diagnosis of AD.~* Has known allergy to humanized monoclonal antibodies.~* Has an ongoing clinically significant laboratory abnormality, as determined by the investigator.~* Has screening MRI with results showing \>4 amyloid related imaging abnormalities H (ARIA-H) micro-hemorrhages or presence of ARIA-E.~* Has any contraindications for MRI studies, including claustrophobia, the presence of metal (ferromagnetic) implants, or a cardiac pacemaker that is not compatible with MRI.~* Has received treatment with a stable dose of an acetylcholinesterase (AChEI) inhibitor or memantine for less than 2 months before randomization. (If a participant has recently stopped AChEIs and/or memantine, he or she must have discontinued treatment at least 2 months before randomization.)

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Solanezumab (Type: EXPERIMENTAL): Solanezumab given intravenously (IV) once every 4 weeks for up to 2 years.
- Placebo (Type: EXPERIMENTAL): Placebo given IV once every 4 weeks for up to 2 years.

Based on this trial design, predict the completion outcome and termination type (if applicable).